Drug intelligence / Profile preview

Paclitaxel, Bevacizumab, and Zoledronic Acid Combination

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

This is a three-drug combination therapy consisting of Paclitaxel (a taxane chemotherapy agent), Bevacizumab (a monoclonal antibody targeting VEGF-A), and Zoledronic acid (a nitrogen-containing bisphosphonate). The combination leverages multiple mechanisms to target cancer cells and their microenvironment. Paclitaxel directly attacks rapidly dividing cancer cells by stabilizing microtubules, preventing cell division. Bevacizumab cuts off the tumor's blood supply by inhibiting angiogenesis via VEGF-A blockade. Zoledronic acid affects bone metabolism and may have anti-angiogenic properties, potentially enhancing the effects of the other drugs while providing bone protection in cases of bone metastases.

Brand names: TaxolAvastinZometa
Other names: Paclitaxel, Bevacizumab, Zoledronic AcidBevacizumab, Paclitaxel, Zoledronic Acid

Targets

FDPS (Farnesyl pyrophosphate synthase)MicrotubuleVEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Paclitaxel, Bevacizumab, and Zoledronic Acid Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paclitaxel, Bevacizumab, and Zoledronic Acid Combination.

Explore the full profile